Works matching IS 21638306 AND DT 2025 AND VI 14 AND IP 2

Results: 17

Population exposure–response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2025, v. 14, n. 2, p. 389, doi. 10.1002/psp4.13283

By:

Wang, Yuchen;
Huh, Yeamin;
Lejeune, Alexandre

Publication type:

Article

MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model‐informed analysis.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2025, v. 14, n. 2, p. 376, doi. 10.1002/psp4.13282

By:

Huestis, Marilyn A.;
Smith, William B.;
Leonowens, Cathrine;
Blanchard, Rebecca;
Viaccoz, Aurélien;
Spargo, Erin;
Miner, Nicholas B.;
Yazar‐Klosinski, Berra

Publication type:

Article

Clinical study design strategies to mitigate confounding effects of time‐dependent clearance on dose optimization of therapeutic antibodies.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2025, v. 14, n. 2, p. 365, doi. 10.1002/psp4.13280

By:

Proctor, Jeffrey R.;
Wong, Harvey

Publication type:

Article

Implementing a Bayesian approach using Stan with Torsten: Population pharmacokinetics analysis of somatrogon.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2025, v. 14, n. 2, p. 351, doi. 10.1002/psp4.13279

By:

Wang, Yuchen;
Pei, Xinyi;
Niu, Tao;
Korth‐Bradley, Joan;
Fostvedt, Luke

Publication type:

Article

A tutorial on pharmacometric Markov models.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2025, v. 14, n. 2, p. 197, doi. 10.1002/psp4.13278

By:

Ooi, Qing Xi;
Plan, Elodie;
Bergstrand, Martin

Publication type:

Article

A theoretical systems chronopharmacology approach for COVID‐19: Modeling circadian regulation of lung infection and potential precision therapies.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2025, v. 14, n. 2, p. 340, doi. 10.1002/psp4.13277

By:

Tseng, Yu‐Yao

Publication type:

Article

Exploration of the potential impact of batch‐to‐batch variability on the establishment of pharmacokinetic bioequivalence for inhalation powder drug products.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2025, v. 14, n. 2, p. 331, doi. 10.1002/psp4.13276

By:

Li, Shuhui;
Feng, Kairui;
Lee, Jieon;
Gong, Yuqing;
Wu, Fang;
Newman, Bryan;
Yoon, Miyoung;
Fang, Lanyan;
Zhao, Liang;
Gobburu, Jogarao V. S.

Publication type:

Article

Exposure–response modeling of liver fat imaging endpoints in non‐alcoholic fatty liver disease populations administered ervogastat alone and co‐administered with clesacostat.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2025, v. 14, n. 2, p. 317, doi. 10.1002/psp4.13275

By:

Hughes, Jim H.;
Amin, Neeta B.;
Wojciechowski, Jessica;
Vourvahis, Manoli

Publication type:

Article

Artificial intelligence modeling of biomarker‐based physiological age: Impact on phase 1 drug‐metabolizing enzyme phenotypes.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2025, v. 14, n. 2, p. 302, doi. 10.1002/psp4.13273

By:

Bhat, Amruta Gajanan;
Ramanathan, Murali

Publication type:

Article

Concentration–QT modeling demonstrates that the selective mineralocorticoid receptor modulator, balcinrenone (AZD9977), does not prolong QT interval.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2025, v. 14, n. 2, p. 292, doi. 10.1002/psp4.13272

By:

Sundell, Jesper;
Rekic, Dinko;
Melin, Johanna;
Johansson, Susanne;
Ebrahimi, Ahmad;
Dota, Corina;
Parkinson, Joanna

Publication type:

Article

Pharmacometric and statistical considerations for dose optimization.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2025, v. 14, n. 2, p. 279, doi. 10.1002/psp4.13271

By:

Chotsiri, Palang;
Yodsawat, Prasert;
Hoglund, Richard M.;
Simpson, Julie A.;
Tarning, Joel

Publication type:

Article

An integrated quantitative systems pharmacology virtual population approach for calibration with oncology efficacy endpoints.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2025, v. 14, n. 2, p. 268, doi. 10.1002/psp4.13270

By:

Braniff, Nathan;
Joshi, Tanvi;
Cassidy, Tyler;
Trogdon, Michael;
Kumar, Rukmini;
Poels, Kamrine;
Allen, Richard;
Musante, Cynthia J.;
Shtylla, Blerta

Publication type:

Article

Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2025, v. 14, n. 2, p. 257, doi. 10.1002/psp4.13264

By:

Crass, Ryan L.;
Prem, Komal;
Gaudreault, Francois;
Lusk, Elizabeth;
Ribeiro, Ramiro;
Chapel, Sunny;
Baumal, Caroline R.

Publication type:

Article

Population pharmacokinetic and pharmacodynamic model of evogliptin: Severe uremia increases the bioavailability of evogliptin.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2025, v. 14, n. 2, p. 246, doi. 10.1002/psp4.13263

By:

Kim, Byungwook;
Kim, Jung Eun;
Lee, Soyoung;
Oh, Jaeseong;
Cho, Joo‐Youn;
Jang, In‐Jin;
Lee, SeungHwan;
Chung, Jae‐Yong;
Yoon, Seonghae

Publication type:

Article

Quantitative pharmacology of dual‐targeted bicistronic CAR‐T‐cell therapy using multiscale mechanistic modeling.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2025, v. 14, n. 2, p. 229, doi. 10.1002/psp4.13259

By:

Su, Mei‐Chi;
Dey, Agnish;
Maddah, Erfan;
Mugundu, Ganesh M.;
Singh, Aman P.

Publication type:

Article

Issue Information.

Published in:: CPT: Pharmacometrics & Systems Pharmacology, 2025, v. 14, n. 2, p. 193, doi. 10.1002/psp4.13169
Publication type:: Article

Uncovering the interleukin‐12 pharmacokinetic desensitization mechanism and its consequences with mathematical modeling.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2025, v. 14, n. 2, p. 217, doi. 10.1002/psp4.13258

By:

DeBonis, Jonathon;
Veiseh, Omid;
Igoshin, Oleg A.

Publication type:

Article